apolipoprotein B in serum/plasma
Jump to navigation
Jump to search
Introduction
see apolipoprotein A1/B in serum
Indications
- evaluation of dyslipidemia
- improves risk prediction for cardiovascular events when added to other traditional risk factors for men > 35 years, women > 45 years (NGC)
- better indicator of cardiovascular risk than LDL cholesterol in statin- treated patients[1]
- only lipid parameter independently associated with risk for myocardial infarction[2]
Clinical significance
- serum apoB > 130 mg/dL is a risk modifier in patients not using statins
- in statin-treated patients, serum apoB target of < 92 mg/dL may be appropriate[1]
More general terms
More specific terms
Additional terms
Component of
- cholesterol LDL/apolipoprotein B in serum/plasma
- cholesterol/apolipoprotein B in serum/plasma
- apolipoprotein B/LDL cholesterol in serum/plasma
- apolipoprotein B/apolipoprotein A1 in serum/plasma
References
- ↑ 1.0 1.1 1.2 Wendling P ApoB May Better Predict Mortality Risk in Statin-Treated Patients. Medscape - Mar 17, 2021. https://www.medscape.com/viewarticle/947631
Lindhardt Johannesen CD, Mortensen MB, Langsted A, Nordestgaard BG, Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients. J Am Coll Cardiol 2021. 77(11):1439-1450 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33736827 https://www.jacc.org/doi/10.1016/j.jacc.2021.01.027
Stone NJ, Lloyd-Jones D Tracking Residual Risk: Time for a Change? J Am Coll Cardiol 2021. 77(11):1451-1453 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33736828 https://www.jacc.org/doi/10.1016/j.jacc.2021.01.035 - ↑ 2.0 2.1 Marston NA, Giugliano RP, Melloni GEM et al. Association of apolipoprotein B-containing lipoproteins and risk of myocardial infarction in individuals with and without atherosclerosis: Distinguishing between particle concentration, type, and content. JAMA Cardiol 2021 Nov 13; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34773460 PMCID: PMC8590731 (available on 2022-11-13) https://jamanetwork.com/journals/jamacardiology/article-abstract/2786333
Sniderman AD, Navar AM, Thanassoulis G et al. Apolipoprotein B vs low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol as the primary measure of apolipoprotein B lipoprotein- related risk: The debate is over. JAMA Cardiol 2021 Nov 13; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34773457 https://jamanetwork.com/journals/jamacardiology/article-abstract/2786334